Skip to main content

Table 3 Helicobacter pylori eradication rates in the ALEB therapy subgroup, combined AFEB therapy subgroup, and LBQT group

From: Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study

Eradication rate

ALEB therapy subgroup (n = 51)

Combined AFEB therapy subgroup (n = 131)

LBQT group (n = 182)

ITT analysis

44/51 (86.3%)

119/131 (90.8%)

118/182 (64.8%)

PP analysis

44/50 (88.0%)

119/129 (92.2%)

118/174 (67.8%)

  1. ALEB (susceptibility-guided therapy) amoxicillin + levofloxacin + esomeprazole + colloidal bismuth pectin, LBQT levofloxacin‐ and bismuth-based quadruple therapy not guided by antibiotic susceptibility, amoxicillin + levofloxacin + esomeprazole + colloidal bismuth pectin, AFEB amoxicillin + furazolidone + esomeprazole + colloidal bismuth pectin, ITT intention‐to‐treat, PP per protocol